BPG is committed to discovery and dissemination of knowledge
Basic Study
Copyright ©The Author(s) 2025.
World J Hepatol. Aug 27, 2025; 17(8): 107456
Published online Aug 27, 2025. doi: 10.4254/wjh.v17.i8.107456
Table 1 Clinical prevalence of rtCYE and rtCYEI mutations in patients infected with different hepatitis B virus genotypes assessed by direct sequencing, n (%)
Mutation(s)
Genotype A (n = 9)
Genotype B (n = 4266)
Genotype C (n = 23718)
Genotype D (n = 243)
rtS106C0 (0.00)56 (1.31)1947 (8.21)1 (0.41)
rtH126Y7 (77.78)75 (1.76)759 (3.20)3 (1.23)
rtD134E0 (0.00)9 (0.21)605 (2.55)0 (0.00)
rtL269I2 (22.22)3939 (92.33)14584 (61.49)231 (95.06)
rtS106C+H126Y0 (0.00)0 (0.00)114 (0.48)0 (0.00)
rtS106C+H126Y+D134E0 (0.00)0 (0.00)6 (0.03)0 (0.00)
rtS106C+H126Y+D134E+L269I0 (0.00)0 (0.00)6 (0.03)0 (0.00)
Table 2 Mutation patterns and clinical information of the patients with hepatitis B virus rtCYE/rtCYEI mutations
Patient
Date1
GT
HBV DNA (log10 IU/mL)
ALT (U/L)
HBeAg
NAs exposure
(month)
Direct sequencing
Clonal sequencing (positive clone number/total tested clone number)
P12009.02C8.1655+LAM (19)rtS106C+H126Y+D134ErtS106C+H126Y+D134E (18/20), rtS106C+H126Y+D134E+L80I+M204I (1/20), rtS106C+H126Y+D134E+L269I (1/20)
P22009.05C8.6653+LdT (18)rtS106C+H126Y+D134E+M204IrtS106C+H126Y+D134E+M204I (19/20), rtS106C+H126Y+D134E+L80I+M204I (1/20)
P32012.04C8.10589+LAM (33)rtS106C+H126Y+D134E+L80I+L180M+M204IrtS106C+H126Y+D134E+L80I+L180M+M204I (17/20), rtS106C+H126Y+D134E+L269I+L80I+L180M+M204I (3/20), rtS106C+H126Y+L80I+L180M+M204I (1/20)
P42013.06C6.77375+ADV (55)rtS106C+H126Y+D134E+L269I+A181VrtS106C+H126Y+D134E+L269I+A181V (17/20), rtH126Y+L269I+A181V (3/20)
P52013.08C1.6020+ADV (17)→ETV (15)rtS106C+H126Y+D134E+L269IrtS106C+H126Y+D134E+L269I (20/20)
P62013.08C5.5220-LdT (16)rtS106C+H126Y+D134E+L269I+M204IrtS106C+H126Y+D134E+L269I (18/20), rtS106C+H126Y+D134E+L269I+M204I (2/20)
P72008.06C5.2137+LAM (24)→ADV (18)rtS106C+H126Y+D134ErtH126Y (6/20), rtS106C+H126Y+D134E (14/20)
P82008.08C6.61109+LdT (16)rtS106C+H126Y+D134E+L80I+M204IrtS106C+H126Y+D134E+L80I+M204I (19/20), rtS106C+H126Y+D134E+L269I+L80I+M204I (1/20)
P92009.04C3.7787-ADV (32)rtS106C+H126Y+D134E+L269I+N236TrtS106C+H126Y+D134E+L269I (16/20), rtS106C+H126Y+D134E+L269I+N236T (4/20)
P102010.08C6.88165-LAM (28)→ADV (12)rtS106C+H126Y+D134ErtS106C+H126Y+D134E (20/20)
P112012.09C4.5035-LAM (38)rtS106C+H126Y+D134E+L269I+M204IrtS106C+H126Y+D134E+L269I+M204I (20/20)
P122014.06C4.1875-LAM (36)→ADV (25)rtS106C+H126Y+D134E+L269IrtS106C+H126Y+D134E+L269I (16/20), rtS106C+H126Y+D134E (4/20)
Table 3 Analysis of clinical features between hepatitis B virus rtCYE/rtCYEI mutation-positive and negative patients, n (%)/median (25th-75th percentiles)

rtCYE/rtCYEI (+) (n = 12)
rtCYE/rtCYEI (-) (n = 28224)
Univariate OR (95%CI)
P value
Age (years) 43 (33-49)42 (32-51)3.78 (-7.88-6.95)0.903
Gender (male)10 (83.33)22419 (79.43)0.77 (0.17-3.53)1.00
Genotype (A/B/C/D%)0/0/100/00.03/15.11/84.00/0.860.515
HBV DNA (log10 IU/mL) 5.37 (3.40-6.69)4.03 (2.72-6.00)0.64 (-1.96-0.56)0.275
ALT (U/L)65.0 (35.5-151.0)38.00 (23.0-72.0)57.48 (-153.95-71.37) 0.473
AST (U/L)33.0 (29.0-114.5)35.0 (25.0-66.0)73.71 (-179.46-109.51)0.635
TBIL (µmol/L)13.85 (12.5-21.1)14.2 (10.2-22.0)20.32 (-29.46-50.21)0.610
HBeAg (+)7 (58.33)17438 (61.78)0.87 (0.28-2.73)0.806
LAM/LdT exposure19 (75.00)15419 (54.63)0.40 (0.11-1.48)0.260
ADV exposure16 (50.00)16971 (60.13)1.51 (0.49-4.68)0.474
ETV exposure11 (8.33)8698 (30.82)4.90 (0.63-37.96)0.169
TDF exposure10 (0.00)390 (1.38)0.986 (0.98-0.99)1.000
TAF exposure100
Table 4 Drug susceptibility analysis of representative hepatitis B virus strains, mean ± SD
Viral strain
Tenofovir disoproxil fumarate
EC50 (μmol/L)2
Fold3
P value1
rtWT (wild-type)5.79 ± 1.591.0-
rtWT (laboratory)5.90 ± 1.951.00.93
rtCYE7.41 ± 0.971.30.09
rtCYEI8.51 ± 1.291.5< 0.05
rtCYE+M204I6.95 ± 0.641.20.17
rtCYE+L80I+L180M+M204I6.92 ± 1.691.20.31
rtCYEI+M204I8.92 ± 0.871.5< 0.05
rtCYEI+L80I+L180M+M204I10.23 ± 1.011.8< 0.05
rtCYEI+A181V36.15 ± 5.996.2< 0.05
rtCYEI+N236T57.33 ± 5.309.9< 0.05